5 Filters

Bayer's decision to suspend work with FleishmanHillard

"The suspension followed a story in French newspaper Le Monde revealing that FleishmanHillard collected names for a reputational campaign.

Bayer has suspended work with external agencies amid a French government investigation into lists of opponents and supporters compiled for what Le Monde called a “media counter-offensive”.

The newspaper reported on Friday that prosecutors in Paris were investigating lists developed to help the company respond to the crisis over its glyphosate-based herbicide, known by the brand name Roundup.

Glyphosate, which has been named in lawsuits as a carcinogen, was developed by Monsanto before Bayer acquired that company.
List of more than 200 people

The lists were created as part of a PR initiative to support glyphosate. They included the names of more than 200 people, including journalists, politicians and agricultural and non-profit leaders categorised by their position on Monsanto.

French law tightly regulates the creation of lists and databases of people based on their political views.

The investigation was prompted by a complaint Le Monde made on 26 April, after it saw one of its journalists’ names on a leaked FleishmanHillard list obtained by reporters covering the glyphosate PR campaign.

Le Monde broke news of the list on Friday.
Agency suspended

In a statement, Bayer apologised for the creation of the list and said it has suspended its co-operation with the “involved external service providers”.

The company said it will ask an external law firm to investigate the project and Matthias Berninger, head of public affairs and sustainability, will “evaluate the issue internally”.

“We are also currently investigating further appropriate consequences both internally and with regard to external parties,” the company said in a statement.

The investigation comes after it was reported this week that a US jury had ordered Bayer to pay more than $2bn in damages to a Californian couple who said Roundup was responsible for their cancers.

It is the third - and most substantial - award of damages against Bayer over Roundup in the US and there are thousands more legal cases in the pipeline. Bayer stock is down approximately 40 per cent since the group acquired Monsanto.

Bayer said the PR initiative supporting glyphosate began before it acquired Monsanto, and the manager in charge of the programme left the company shortly after the acquisition closed.
Crisis comms reaction

Commenting on the investigation, Sam Rogers, commercial director at crisis comms agency Rampart PR, said: “Bayer has tried to distance itself from the list compilation ‘crisis’ by suspending its relationship with FleishmannHillard [and] putting out a statement disagreeing with FH’s approach to relationship-building. Having just had a $2bn ruling against them for giving people cancer, it’s tempting to conclude this was more a commercial decision than a moral one.”

Rogers said FleishmanHillard should brace itself for further fallout.

He added: “Perhaps Bayer is gearing up for a lawsuit against FH to recover some of that payment. If so, that will truly put FH’s crisis comms skills to the test.”

FleishmanHillard declined to discuss the issue, but said in a statement that it was proud of its work with Bayer and that it conducts itself “in keeping with the professional standards and established practices of our industry”.

Fellow Bayer agency partner Publicis Consultants also declined to talk about the controversy, but said in a statement that between October 2016 and April 2017, it had “delivered public affairs work using public data for another PR agency”.

Publicis added that it is conducting an internal audit of that work and that it operates according to the highest legal and ethical standards.
Escalating crisis

Another crisis comms expert, Jonathan Hemus, managing director of Insignia, said the evolving crisis had been compounded by the investigation into the controversial list.

He said: “This development… highlights the need for your crisis management planning to include a clear understanding of all relevant regulations and requirements ahead of time, rather than falling foul of them when the heat is on.”

Hemus added: “It’s a salutary reminder that dealing with journalists is challenging enough under the pressure of a crisis without making your task even harder by turning the media into an aggrieved stakeholder as well.”

In addition to the French investigation, the list could prompt an inquiry in Belgium.

Philippe Lamberts, a member of the European Parliament based in Brussels who was included on the list, told Le Monde that he plans to file a complaint with a Belgian court.
A version of this story first appeared in PRWeek US" https://www.prweek.com/article/1584655/crisis-experts-respond-bayer-suspends-agency-controversial-list

1 Like

tl;dr: bad guys line up scapegoat for doing what they wanted all along

Less cynically, at least some journalists somewhere* are trying to dig beneath the surface.

*For which read ‘outside the AngloZionosphere’

1 Like

"Chemicals giant Bayer AG is reeling after a jury awarded $2 billion in damages to people who say they contracted cancer after years of using Roundup, a popular weed killer manufactured by Bayer subsidiary Monsanto Co. Bayer probably won’t pay out the full $2 billion. But more than 10,000 further cases are pending, worrying Bayer investors as well as farmers who rely on the product as a cheap, effective herbicide.

Cancer may only be part of the story. Studies over the past decade suggestthat glyphosate — the active ingredient in Roundup — pollutes water sources, hangs around in soil far longer than previously suspected, and routinely taints human food supplies. In both the U.S. and Europe, the supposedly safe limits for human ingestion are based on long-outdated science. Research also points to serious adverse consequences for the environment, and there are indications glyphosate can cause disease in mammals even several generations removed from the initial exposure.

Glyphosate isn’t as safe as its manufacturers would like us to believe, and steep reduction in its use is probably long overdue.

Monsanto patented glyphosate in the early 1970s, and it rapidly became the global go-to chemical for weed control as the commercial product Roundup. Executives at Monsanto encouraged the spread of Roundup by engineering genetically modified seeds for corn and other crops that can tolerate glyphosate.

Glyphosate manufacturers — which now include many companies around the world; Monsanto’s patent expired in 2000 — have long argued that glyphosate is completely safe for humans, animals and indeed all non-plant life. It works by inhibiting a biochemical pathway that plants need to grow, and animals don’t share that pathway, which is superficially reassuring. But it only means that glyphosate shouldn’t starve animals to death, as it does plants. Chemicals can exert effects on organisms in myriad ways.

Interpreting the evidence for cancer isn’t easy, because different panels have come to contrasting conclusions by using different procedures. In 2015, the International Agency for Research on Cancer, part of the World Health Organization, concluded that glyphosate is likely carcinogenic. But both the U.S. Environmental Protection Agency and the European Food Safety Authority have declined to do the same. Both the EPA and the EFSA relied on information provided by researchers linked to the industry and considered studies provided by the industry that were not peer-reviewed or made public. The IARC relied solely on publicly available peer-reviewed research.

An international team of biologists reviewed the IARC and EFSA studies, concluding that the latter were significantly flawed and departed from standard hazard-assessment practices.

There are plenty of other reasons to be concerned about glyphosate. An independent group of biologists in 2016 tried to clarify what we really know about the chemical. Their paper makes for grim reading. It noted that studies in the previous decade found significant traces of glyphosate-based herbicidesindrinking water and groundwater, probably routinely exposing millions of people across the planet to the chemical. Toxicity studies in rodents have found that glyphosate can damage the liver and kidneys, even for doses in the range generally considered safe for humans. Young pigs fed soybeans contaminated with glyphosate herbicide residues have exhibited congenital malformations, not unlike birth defects observed for people living in and near farming regions with intensive glyphosate use.

The study points to many other troubling findings, from the disruptive impact of glyphosate on hormone signaling in mammals to how the chemical binds to metals such as zinc, cobalt and manganese, reducing the supplies of these crucial micronutrients for people, crops and other plants, and wildlife. Most of these effects would probably not be detected by the traditional toxicology test guidelines currently favored by pesticide regulators.

In April, a different study found another worrying effect: Glyphosate might disrupt biological functions for generations. One of the hottest topics in biology in recent years has been epigenetics — the study of how offspring inherit not only the genes of their parents, but also certain patterns of chemical activity written onto those genes by other signaling molecules. This offers a means by which environmental factors that affect an organism during its life can be passed down to its offspring. In experiments with rats fed glyphosate, Michael Skinner of Washington State University and colleagues found that malign effects of treatment did not show up in the organism eating glyphosate, or even in its offspring, but in the next two generations of offspring. These rats, without ever being exposed to glyphosate, nevertheless showed a prominent tendency toward prostate disease, obesity, kidney disease, ovarian disease and birth abnormalities.

Glyphosate is clearly not a benign herbicide warranting no concern, its link to cancer aside. It may be causing many other serious disruptions to human biology, and to organisms and plants in the environment, currently invisible to today’s outdated regulatory systems. It’s about time our regulators updated their science.

Exposure to Chemical in Roundup Increases Risk for Cancer 41%, Study Finds" https://www.gmonion.com/roundups-risks-could-go-well-beyond-cancer/

"Records Show EPA Efforts To Slow Herbicide Review Came In Coordination With Monsanto

Newly released government email communications show a persistent effort by multiple officials within the Environmental Protection Agency (EPA) to slow a separate federal agency’s safety review of Monsanto’s top-selling herbicide. Notably, the records demonstrate that the EPA efforts came at the behest of Monsanto, and that EPA officials were helpful enough to keep the chemical giant updated on their progress.

The communications, most of which were obtained through Freedom of Information Act (FOIA) requests, show that it was early 2015 when the EPA and Monsanto began working in concert to stall a toxicology review that a unit tied to the Centers for Disease Control and Prevention (CDC) was conducting on glyphosate, the key ingredient in Monsanto’s branded Roundup herbicide products. The details revealed in the documents come as Monsanto is defending itself against lawsuits alleging that it has tried to cover up evidence of harm with its herbicides.

The Agency for Toxic Substances and Disease Registry (ATSDR), a federal public health agency that along with the CDC is part of the U.S. Department of Health and Human Services (HHS), is charged with evaluating the potential adverse human health effects from exposures to hazardous substances in the environment. So it made sense for the ATSDR to take a look at glyphosate, which is widely used on U.S. farms, residential lawns and gardens, school playgrounds and golf courses. Glyphosate is widely used in food production and glyphosate residues have been found in testing of human urine.

The ATSDR announced in February 2015 that it planned to publish a toxicological profile of glyphosate by October of that year. But by October, that review was on hold, and to this date no such review has yet been published. (Update: the draft review was finally published in April 2019.) The documents reveal this was no accident, no bureaucratic delay, but rather was the result of a collaborative effort between Monsanto and a group of high-ranking EPA officials.

For Monsanto, the timing of the ATSDR review was worrisome. In March 2015, the World Health Organization’s International Agency for Research on Cancer (IARC) had declared glyphosate to be a probable human carcinogen, and Monsanto feared ATSDR might have similar concerns about the chemical. Previous reports have described how one EPA official, Jess Rowland, communicated to Monsanto in April 2015 his willingness to try to kill the ATSDR review. Rowland, who retired in 2016, was the deputy division director within the health effects division of the EPA’s Office of Pesticide Programs (OPP). Allegations of collusion between Rowland and Monsanto have prompted a probe by the EPA’s Office of Inspector General.

But the trove of documents newly obtained from within EPA and HHS demonstrate that the assistance to Monsanto came not only from Rowland but also from even higher-level EPA officials. Rather than encourage and assist the toxicology review of glyphosate, Monsanto and EPA officials repeatedly complained to ATSDR and HHS that such a review was unnecessarily “duplicative” and should take a back seat to an EPA review also underway.

The following timeline shows how the events unfolded:

May 19, 2015 – Michael Dykes, who at that time was Monsanto’s long-time vice president of government affairs, wrote directly to the EPA’s Jim Jones, the Assistant Administrator for the Office of Chemical Safety & Pollution Prevention. Jones had oversight of the EPA’s Office of Pesticide Programs (OPP) and was a presidential appointee who carried significant clout. The afternoon was waning when the email came in at 3:28 p.m. Dykes reminded Jones that they had recently discussed the HHS’ ATSDR glyphosate review at a meeting.

“You were not aware of their review. Did you learn anything more about their efforts?” Dykes asked.

Jones did not waste time. Roughly an hour later he forwarded the message to OPP Director Jack Housenger, writing “Monsanto thinks atsdr is doing a glyphosate Assessment. Could you guys run that down?” Housenger responds quickly: “Yes. Jess checked with them…. It has been difficult to get information.”

Within an hour Jones instructed a member of his staff to get him contact information for the head person responsible for ATSDR. She replied the next morning that Dr. Patrick Breysse was the point person. Breysse joined the CDC in 2014 as director of its National Center for Environmental Health, overseeing the NCEH’s ATSDR.

May 20, 2015 It was only a little after 8:30 a.m. but Jones told the staff member to instruct Housenger to get in touch with Breysse, and within two hours Housenger had penned an email to Breysse explaining that an EPA’s own re-evaluation/risk assessment of glyphosate was nearing completion, and asking Breysse if “you would still feel the need to do your assessment.” Housenger told Breysse that he already had reached the individual assigned to the ATSDR assessment and she had indicated she would “coordinate” with EPA, but that was not sufficient. Housenger did not mention Monsanto’s outreach to EPA on the issue, but instead questioned “whether this is a good use of government resources” for ATSDR to continue with its review. Breysse responded that he would “look into this” and Housenger thanked him for his quick response. Breysse then reached out to an ATSDR division director named James Stephens to arrange a discussion about the EPA request.

May 21, 2015 James Stephens wrote back to Patrick Breysse that the ATSDR team thought the EPA work “overlaps but isn’t totally duplicative…” and stated that the ASTDR team has not been able to see draft copies of the EPA’s work. “I think we would all welcome further discussion with EPA but would hope to use it to help us find out more about what they are doing, ” he told Breysse. After hearing from Stephens, Breysse wrote back to Housenger saying ATSDR staff would be in touch to discuss. Housenger replied with his reiteration that the ATSDR review would be a “duplicative government effort” and that the EPA draft would be out in July of 2015. (As of this writing, that EPA preliminary risk assessment still has not been released, though in 2016 the EPA did release a cancer assessment report that declared glyphosate was not likely to cause cancer.)

June 4, 2015 Pressing the issue, EPA’s Housenger wrote again to Breysee to say he had not heard from anyone yet**.** The ATSDR’s Stephens wrote back promising to make sure “someone gives you a ring.” Internal Monsanto emails show that at the same time, Monsanto was also pushing the “duplicative” narrative with HHS, meeting on June 4 with HHS Deputy Assistant Secretary for Global Health Mitchel Wolfe to ask him to help repudiate the IARC classification and to recognize that a review of glyphosate was “not the primary role” for his agency. “Dr. Wolfe said he would follow up on what was going on with ATSDR and he was encouraged to have discussions with EPA staff, as well,” a Monsanto memo detailing the meeting states.

June 9, 2015 Henry Abadin, an ATSDR supervisory scientist, reported to Stephens that he had talked with Housenger and explained that the agency did not believe it was “duplicating efforts.” Nevertheless, he said he told EPA, “we did not have a problem with putting the glyphosate profile on hold, pending the OPP final report.”

June 19, 2015 To further ensure the ATSDR review didn’t move forward, Monsanto’s Dykes talked again with HHS’s Wolfe, asking for an update on ATSDR. “I explained… our question was about the purpose and scope of such a duplicative review by ATSDR. I also told him that we were concerned that ATSDR may come out any day with a report. I again stressed that we were concerned that they were even reviewing glyphosate as were the people we talked with at EPA,” Dykes wrote to colleagues.

June 21, 2015 It was a Sunday, but Monsanto’s Dykes was still concerned enough about the ATSDR review to copy multiple colleagues on a late night email to report that he had continued to press the “duplicative” point with ATSDR but was concerned about a “glyphosate review coming any day.” In a text message sent that same day, Monsanto scientist Eric Sachs reached out to a former EPA toxicologist named Mary Manibusan asking for contacts at ATSDR. “We’re trying to do everything we can to keep from having a domestic IARC occur w this group. may need your help,” Sachs wrote. The text messages were among certain internal Monsanto records obtained by cancer victims who are suing Monsanto alleging Roundup caused their diseases.

June 23, 2015 By Tuesday, Monsanto’s Jenkins had good news: He had heard from Housenger that the EPA official had been successful in garnering a promise from ATSDR to put its report “on hold.” The review was not dead, however, he wrote: ATSDR argues “that their process is distinguishable and not duplicative. They look at different endpoints and told EPA they don’t “make a call on cancer”, but I think we should continue to be cautious.”

On June 24, 2015 Monsanto’s chief scientist William Heydens responded: “’Distinguishable and not duplicative’? Seriously? And I will believe the not ‘making a call on cancer’ part when I see it. Anyway, at least they know they are being watched, and hopefully that keeps them from doing anything too stupid…” Jenkins wrote back, acknowledging that Monsanto had much more to fear from ATSDR than EPA as the two agencies had arrived at “different conclusions” on other issues. He reported he had been told ATSDR was “VERY conservative and IARC like…”

By October 23, 2015 EPA and Monsanto had the ATSDR review fully on hold. EPA’s Housenger wrote to update Monsanto’s Jenkins: “They are waiting for our glyphosate RA. And they agreed to share what they do.”

That same month, the EPA’s Cancer Assessment Review Committee (CARC), which was chaired by Rowland, issued an internal report stating that contrary to IARC, the EPA’s review of glyphosate found it “not likely to be carcinogenic to humans.”

The EPA still has yet to issue the overall new risk assessment it said would be out in 2015. The agency has offered ever-changing timelines for the assessment, but now says its intends to release a draft risk assessment sometime this year. That will be followed by a 60-day public comment period. After the public comment period the EPA will determine whether any risk management is needed. In the meantime, Monsanto has cited the EPA’s backing of glyphosate safety as repudiation of the IARC finding both in court and with regulators in Europe who are also looking at glyphosate safety issues.

The EPA did not respond to a request for comment about its efforts to delay the ATSDR report or communications with Monsanto regarding that effort.

But Brent Wisner, a lawyer representing many of the cancer victims who are suing Monsanto, said the documents offer damning evidence of improperly close ties between the EPA and the chemical company. “I think it’s very clear… that EPA officials and Monsanto employees worked together to accomplish a goal of stopping that analysis at ATSDR. That is collusion. I don’t know what else you’d call that,” said Wisner.

For its part, the ATSDR said this week that the review it started in 2015 “is not complete” but that it anticipates a draft glyphosate toxicological profile to be issued for public comment by the end of this year. A spokesperson for the agency declined to discuss the circumstances surrounding the delay in the review.

And Jones, whose EPA job ended when the Trump administration took over, defended his responsiveness to Monsanto’s concern about the ATSDR review, saying it had only to do with the “efficient use of government resources.”

“Had any party contacted me and informed me that another agency within the Administration was simultaneously assessing a chemical as my organization, I would have intervened,” Jones said. “There is no value to the same government investing limited resources to work on the same issue. As you know resources at the federal level were and are scarce which made duplication even more problematic.” Jones said additionally that “when two organizations assess the same chemical, it is very likely there will be differences in their assessments. Even when these differences don’t matter from a public health perspective, an enormous amount of energy is spent attempting to resolve these differences” and that is not ultimately in the “public interest.”

Pesticides ATSDR, Cancer Assessment Review Committee (CARC), EPA, glyphosate review, HHS, IARC, Jack Housenger, James Stephens, Jess Rowland, Jim Jones, Mary Manibusan, Michael Dykes, Monsanto, OPP, Patrick Breysse, William Heydens" https://usrtk.org/pesticides/read-the-emails-texts-that-show-epa-efforts-to-slow-atsdr-glyphosate-review/